glp-1 obesity drug news today oct 23 2025 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Poll: 1 in 8 Adults
Description
Available for both RF and RM licensing.
That third pathway matters
This analysis of survey data finds that over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug though relatively few have a claim, suggesting that a much smaller share seeks treatment through healthcare providers.
That's why we are urging the FDA to strengthen safeguards and help ensure patients have access to medicines that meet rigorous quality and safety standards
New data is illuminating the full profile of GLP-1 side effects
